Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna Therapeutics (MDNAF) has completed enrollment of 152 patients in its global Phase 1/2 ABILITY-1 study of investigational cancer therapy MDNA11.
The study evaluates MDNA11 alone and in combination with Merck’s KEYTRUDA (pembrolizumab), with patients enrolled across Canada, the United States, Australia, Europe and South Korea. Updated study data will be presented at the Society for Immunotherapy of Cancer annual meeting on November 7, 2026. Medicenna will discuss the findings during a live expert webinar on November 10, from 9:00 to 10:00 a.m. EST, featuring management and physicians Hussein A. Tawbi and André Mansinho.
Medicenna Therapeutics (MDNAF) reported preclinical MDNA209 results showing longer survival in two aggressive mouse models of acute graft-versus-host disease. Long-acting MDNA209 improved symptoms, with median survival reaching 23.5 and 26 days, versus 7 days in each control group. Body weight recovery followed initial transplant-related loss.
MDNA209 blocked CD122, a receptor component involved in IL-2 and IL-15 immune signaling. In one human T-cell signaling assay, it was approximately 150 times more potent than Mikβ1 and 10 times more potent than a daclizumab biosimilar. Other laboratory findings included reduced immune-cell expansion and inflammatory signaling; four days of treatment did not reduce human regulatory T-cell viability. The findings were presented on October 23, 2026, in Paris. Medicenna is pursuing potential partnership opportunities for MDNA209.
Medicenna Therapeutics (MDNAF) will present new preclinical data on MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference.
Dr. Minh D. To will deliver the presentation on October 23, 2026, from 4:30–5:00 PM CEST in Paris, France. MDNA209 is an engineered protein designed to block CD122, a component of the receptors for the immune signaling molecules IL-2 and IL-15, and inhibit signaling by both molecules. The company says the presentation will further characterize MDNA209’s potency and approach to targeting these pathways.
Medicenna Therapeutics (MDNAF) announced that topline MDNA11 study data will be presented orally at SITC on November 7, 2026.
The Phase 1/2 ABILITY-1 trial evaluates MDNA11 in expansion cohorts of patients with advanced and metastatic gastrointestinal, endometrial and melanoma cancers. Abstract 517 was selected among the meeting's Top 150 Abstracts. Its title describes clinical activity in gastrointestinal malignancies selected using biological markers, with MDNA11 alone and with pembrolizumab, including disease resistant to immune checkpoint inhibitors.
The presentation is scheduled for 4:30–4:45 p.m. MST in Oral Session 3 at the Phoenix Convention Center, Room 301D, in Phoenix, Arizona.
Medicenna Therapeutics (MDNAF) shareholders authorized a potential share consolidation at the annual general and special meeting held October 1, 2026. The board may choose a ratio of one post-consolidation share for every 2 to 20 pre-consolidation shares, or decide not to proceed. Any implementation requires regulatory approvals; the ratio and effective date would be announced once the board decides to proceed.
The company said consolidation could support minimum bid-price compliance for a potential major U.S. exchange listing and attract investors with minimum share-price requirements. A listing would still require satisfaction of all applicable requirements and exchange approval. Shareholders also elected all four director nominees, each with more than 97% support, and reappointed MNP as auditor. 31.82% of outstanding common shares were represented at the meeting.
Medicenna (MDNAF) will present an analysis of bizaxofusp survival outcomes in recurrent glioblastoma at SNO 2026 on November 13.
The analysis concerns unresectable, IDH-wildtype recurrent glioblastoma in the intended Phase 3 population and uses a propensity score-weighted external control arm. Nicholas Butowski is scheduled to give the oral presentation at 10:36 a.m. ET in Philadelphia.
Medicenna Therapeutics (MDNAF) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. President and CEO Dr. Fahar Merchant is scheduled to present on September 16, 2026, from 12:00 PM to 12:30 PM EST at the Lotte New York Palace Hotel.
The presentation will be held in the Kennedy II room on the 4th floor and will be webcast live, with replay access available for 90 days via the investor relations Events & Presentations section of Medicenna’s website. Investors can also request one-on-one meetings with Dr. Merchant through conference registration or their H.C. Wainwright representative.
Medicenna Therapeutics (OTCQX: MDNAF) reported fiscal Q1 2027 results for the quarter ended June 30, 2026, and updated progress across its Superkine pipeline. Cash and cash equivalents were $5.7 million versus $6.3 million on March 31, 2026, boosted by $4.4 million in gross proceeds from a public offering and, subsequent to quarter end, $1.3 million from the Australian R&D incentive program.
The company entered a term sheet for a structured financing with Sorbie that may result in approximately $8.0 million, subject to closing conditions, which, together with existing funds, is expected to support planned spending into calendar Q2 2027. MDNA11’s Phase 1/2 ABILITY-1 enrollment remains on track to complete in Q3 2026, with previously reported response rates in the 30–40% range, and updated data plus bizaxofusp results to be presented in upcoming oral conference sessions. NEO-CYT continues enrolling melanoma patients, and planning is underway for an IND and 2027 Phase 1 trial of MDNA113.
Medicenna Therapeutics (OTCQX:MDNAF) reported fiscal 2026 results and pipeline progress. MDNA11 showed 30–40% response rates in Phase 1/2 ABILITY-1 across difficult solid tumors, with updated data and a Phase 2b strategy expected by late 2026. MDNA113 preclinical data supported IND-enabling studies targeting an IND filing in Q4 2026. Bizaxofusp remains Phase 3–ready for recurrent GBM while partnership discussions continue.
Cash was $6.3M at March 31, 2026, plus a $4.4M unit offering and a Sorbie financing term sheet (up to about $8M, outcome uncertain). Operating costs were $22.4M; net loss was $18.4M (vs $11.8M in 2025).
Medicenna (OTCQX: MDNAF) announced two newly issued U.S. patents and one allowed U.S. patent application covering its IL-4 and IL-13 Superkine platforms, including bizaxofusp, and extending to cellular immunotherapy and CNS tumor combination therapies.
According to Medicenna, its global Superkine patent portfolio now exceeds 100 active granted patents and applications across key markets.